Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioAge Labs (BIOA) Current Deferred Revenue (2024 - 2025)

BioAge Labs (BIOA) has disclosed Current Deferred Revenue for 2 consecutive years, with $5.8 million as the latest value for Q4 2025.

  • Quarterly Current Deferred Revenue fell 26.48% to $5.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.8 million through Dec 2025, down 26.48% year-over-year, with the annual reading at $5.8 million for FY2025, 26.48% down from the prior year.
  • Current Deferred Revenue hit $5.8 million in Q4 2025 for BioAge Labs, down from $7.5 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $8.2 million in Q1 2025 to a low of $5.8 million in Q4 2025.